Biodesix Inc. already has a couple of proteomics-based blood tests on the market to help physicians determine the optimal treatment for a patient's lung cancer. The Boulder, Colo.-based startup expects that it has enough cash on hand to propel it to breakeven and is on track for an eventual IPO. Read More
